{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:13:58Z","timestamp":1783671238508,"version":"3.55.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2026,7,10]]},"DOI":"10.1038\/s41415-026-9628-4","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:24:34Z","timestamp":1783668274000},"page":"43-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medication-related osteonecrosis of the jaw in multiple myeloma patients: a case series"],"prefix":"10.1038","volume":"241","author":[{"given":"Louis","family":"Madden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot","family":"Pierse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"9628_CR6301","doi-asserted-by":"crossref","unstructured":"Ruggiero S L, Dodson T B, Aghaloo T, Carlson E R, Ward B B, Kademani D. American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the Jaws \u2013 2022 update. J Oral Maxillofac Surg 2022; 80: 920\u2013943.","DOI":"10.1016\/j.joms.2022.02.008"},{"key":"9628_CR6304","doi-asserted-by":"crossref","unstructured":"Thumbigere-Math V, Tu L, Huckabay S et al. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol 2012; 35: 386\u2013392.","DOI":"10.1097\/COC.0b013e3182155fcb"},{"key":"9628_CR6306","doi-asserted-by":"crossref","unstructured":"Thumbigere-Math V, Sabino M C, Gopalakrishnan R et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009; 67: 1904\u20131913.","DOI":"10.1016\/j.joms.2009.04.051"},{"key":"9628_CR6308","doi-asserted-by":"crossref","unstructured":"Cheng A, Daly C G, Logan R M, Stein B, Goss A N. Alveolar bone and the bisphosphonates. Aust Dent J 2009; 54: 51\u201361.","DOI":"10.1111\/j.1834-7819.2009.01143.x"},{"key":"9628_CR6310","unstructured":"National Health Service. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw: Dental Clinical Guidance. 2017. Available at https:\/\/www.sdcep.org.uk\/published-guidance\/medication-related-osteonecrosis-of-the-jaw\/ (accessed 1 June 2026)."},{"key":"9628_CR6313","unstructured":"Royal College of Surgeons of England, British Society for Disability and Oral Health. The Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and\/or Bone Marrow Transplantation: Clinical Guidelines. 2018. Available at https:\/\/www.rcseng.ac.uk\/-\/media\/files\/rcs\/fds\/publications\/rcs-oncology-guideline-update--v36.pdf (accessed 1 June 2026)."},{"key":"9628_CR6317","doi-asserted-by":"crossref","unstructured":"Rugani P, Walter C, Kirnbauer B, Acham S, Begus-Nahrman Y, Jakse N. Prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma. Dent J 2016; 4: 32.","DOI":"10.3390\/dj4040032"},{"key":"9628_CR6319","doi-asserted-by":"crossref","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet 2015; 385: 2197\u20132208.","DOI":"10.1016\/S0140-6736(14)60493-1"},{"key":"9628_CR6321","doi-asserted-by":"crossref","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 2016; 43: 676\u2013681.","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"9628_CR6323","doi-asserted-by":"crossref","unstructured":"Cowan A J, Allen C, Barac A et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol 2018; 4: 1221\u20131227.","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"9628_CR6325","doi-asserted-by":"crossref","unstructured":"Turesson I, Bjorkholm M, Blimark C H, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol 2018; 101: 237\u2013244.","DOI":"10.1111\/ejh.13083"},{"key":"9628_CR6328","doi-asserted-by":"crossref","unstructured":"Rajkumar S V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 2020; 95: 548\u2013567.","DOI":"10.1002\/ajh.25791"},{"key":"9628_CR6330","doi-asserted-by":"crossref","unstructured":"Rajkumar S V, Dimopoulos M A, Palumbo A et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: 538\u2013548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"9628_CR6332","doi-asserted-by":"crossref","unstructured":"Terpos E, Morgan G, Dimopoulos M A et al. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013; 31: 2347\u20132357.","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"9628_CR6334","doi-asserted-by":"crossref","unstructured":"Dowling M, Kelly M, Meenaghan T. Multiple myeloma: managing a complex blood cancer. Br J Nurs 2016; 25: 18\u201328.","DOI":"10.12968\/bjon.2016.25.S18"},{"key":"9628_CR6337","doi-asserted-by":"crossref","unstructured":"Terpos E, Kleber M, Engelhardt M et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 2015; 100: 1254\u20131266.","DOI":"10.3324\/haematol.2014.117176"},{"key":"9628_CR6339","doi-asserted-by":"crossref","unstructured":"Silbermann R, Roodman G D. Myeloma bone disease: pathophysiology and management. J Bone Oncol 2013; 2: 59\u201369.","DOI":"10.1016\/j.jbo.2013.04.001"},{"key":"9628_CR6341","doi-asserted-by":"crossref","unstructured":"Kumar S K, Rajkumar S V, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516\u20132520.","DOI":"10.1182\/blood-2007-10-116129"},{"key":"9628_CR6343","doi-asserted-by":"crossref","unstructured":"Daniel K G, Kuhn D J, Kazi A, Dou Q P. Anti-angiogenic and anti-tumor properties of proteasome inhibitors. Curr Cancer Drug Targets 2005; 5: 529\u2013541.","DOI":"10.2174\/156800905774574075"},{"key":"9628_CR6347","doi-asserted-by":"crossref","unstructured":"Quach H, Ritchie D, Stewart A K et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24: 22\u201332.","DOI":"10.1038\/leu.2009.236"},{"key":"9628_CR6350","doi-asserted-by":"crossref","unstructured":"Patel V, Mansi J, Ghosh S et al. MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. Br Dent J 2018; 224: 74\u201379.","DOI":"10.1038\/sj.bdj.2017.1039"},{"key":"9628_CR6352","doi-asserted-by":"crossref","unstructured":"Yarom N, Shapiro C L, Peterson D E et al. Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37: 2270\u20132290.","DOI":"10.1200\/JCO.19.01186"},{"key":"9628_CR6355","doi-asserted-by":"crossref","unstructured":"Srivastava A, Nogueras Gonzalez G M, Geng Y et al. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer 2021; 29: 2305\u20132317.","DOI":"10.1007\/s00520-020-05882-3"},{"key":"9628_CR6357","doi-asserted-by":"crossref","unstructured":"Limones A, S\u00e1ez-Alcaide L M, D\u00edaz-Parre\u00f1o S A, Helm A, Bornstein M M, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal 2020; 25: 326\u2013336.","DOI":"10.4317\/medoral.23324"},{"key":"9628_CR6359","doi-asserted-by":"crossref","unstructured":"Ikesue H, Doi K, Morimoto M et al. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer 2022; 30: 2341\u20132348.","DOI":"10.1007\/s00520-021-06634-7"},{"key":"9628_CR6362","doi-asserted-by":"crossref","unstructured":"Hallmer F, Bjarnadottir O, G\u00f6trick B, Malmstr\u00f6m P, Andersson G. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol 2020; 130: 252\u2013257.","DOI":"10.1016\/j.oooo.2020.04.808"},{"key":"9628_CR6364","unstructured":"Baur D A, Altay M A, Teich S, Schmitt Oswald M, Quereshy F A. Osteonecrosis of the jaw in a patient on raloxifene: a case report. Quintessence Int 2015; 46: 423\u2013428."},{"key":"9628_CR6366","unstructured":"Bindakhil M, Shanti R M, Mupparapu M. Raloxifene-induced osteonecrosis of the jaw (MRONJ) with no exposure to bisphosphonates: clinical and radiographic findings. Quintessence Int 2021; 52: 258\u2013263."},{"key":"9628_CR6368","doi-asserted-by":"crossref","unstructured":"Tzermpos F, Ismail A, Pavli M, Tosios K I. Osteonecrosis of the mandible in a patient with lung adenocarcinoma undergoing anti-angiogenic therapy with bevacizumab. Oral Surg 2016; 9: 40\u201346.","DOI":"10.1111\/ors.12153"},{"key":"9628_CR6370","doi-asserted-by":"crossref","unstructured":"Srivastava A, Nogueras Gonzalez G M, Geng Y et al. Medication-related osteonecrosis of the jaw in patients treated concurrently with antiresorptive and antiangiogenic agents: systematic review and meta-analysis. J Immunother Precis Oncol 2021; 4: 196\u2013207.","DOI":"10.36401\/JIPO-21-14"},{"key":"9628_CR6374","doi-asserted-by":"crossref","unstructured":"Pimolbutr K, Porter S, Fedele S. Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-na\u00efve patient: a comprehensive review of the literature. Biomed Res Int 2018; DOI: 10.1155\/2018\/8071579.","DOI":"10.1155\/2018\/8071579"},{"key":"9628_CR6376","doi-asserted-by":"crossref","unstructured":"Van Poznak C, Reynolds E L, Estilo C L et al. Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. Oral Dis 2022; 28: 193\u2013201.","DOI":"10.1111\/odi.13746"},{"key":"9628_CR6378","doi-asserted-by":"crossref","unstructured":"Saad F, Brown J E, Van Poznak C et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341\u20131347.","DOI":"10.1093\/annonc\/mdr435"},{"key":"9628_CR6380","doi-asserted-by":"crossref","unstructured":"Guarneri V, Miles D, Robert N et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122: 181\u2013188.","DOI":"10.1007\/s10549-010-0866-3"},{"key":"9628_CR6383","doi-asserted-by":"crossref","unstructured":"van Cann T, Loyson T, Verbiest A et al. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 2018; 26: 869\u2013878.","DOI":"10.1007\/s00520-017-3903-5"},{"key":"9628_CR6385","doi-asserted-by":"crossref","unstructured":"Furukawa S, Oobu K, Moriyama M et al. Oral methotrexate-related lymphoproliferative disease presenting with severe osteonecrosis of the jaw: a case report and literature review. Intern Med 2018; 57: 575\u2013581.","DOI":"10.2169\/internalmedicine.8946-17"},{"key":"9628_CR6387","doi-asserted-by":"crossref","unstructured":"Henien M, Carey B, Hullah E, Sproat C, Patel V. Methotrexate-associated osteonecrosis of the jaw: a report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol 2017; 124: 283\u2013287.","DOI":"10.1016\/j.oooo.2017.09.005"},{"key":"9628_CR6390","doi-asserted-by":"crossref","unstructured":"Milosavljevi\u0107 M, Jovanovi\u0107 M, Foli\u0107 M et al. Possible association of methotrexate use with osteonecrosis of the jaw: systematic review. J Stomatol Oral Maxillofac Surg 2022; 123: 458\u2013463.","DOI":"10.1016\/j.jormas.2022.03.012"},{"key":"9628_CR6392","doi-asserted-by":"crossref","unstructured":"Hasegawa T, Hayashida S, Kondo E et al. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. Osteoporos Int 2019; 30: 231\u2013239.","DOI":"10.1007\/s00198-018-4746-8"},{"key":"9628_CR6394","doi-asserted-by":"crossref","unstructured":"Feng Z, An J, Zhang Y. Factors influencing severity of medication-related osteonecrosis of the jaw: a retrospective study. J Oral Maxillofac Surg 2021; 79: 1683\u20131688.","DOI":"10.1016\/j.joms.2020.12.045"},{"key":"9628_CR6397","doi-asserted-by":"crossref","unstructured":"Nisi M, La Ferla F, Karapetsa D et al. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. Int J Oral Maxillofac Surg 2015; 44: 586\u2013591.","DOI":"10.1016\/j.ijom.2015.01.014"},{"key":"9628_CR6400","doi-asserted-by":"crossref","unstructured":"Veszelyn\u00e9 Kot\u00e1n E, Bartha-Lieb T, Parisek Z, Mesk\u00f3 A, Vaszilk\u00f3 M, Hank\u00f3 B. Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients. BMJ Open 2019; 9(5): e025600.","DOI":"10.1136\/bmjopen-2018-025600"},{"key":"9628_CR6402","doi-asserted-by":"crossref","unstructured":"McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 2018; 24: 527\u2013536.","DOI":"10.1111\/odi.12708"},{"key":"9628_CR6404","doi-asserted-by":"crossref","unstructured":"Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18: 2015\u20132019.","DOI":"10.1093\/annonc\/mdm370"},{"key":"9628_CR6406","doi-asserted-by":"crossref","unstructured":"Dodson T B. The frequency of medication-related osteonecrosis of the jaw and its associated risk factors. Oral Maxillofac Surg Clin North Am 2015; 27: 509\u2013516.","DOI":"10.1016\/j.coms.2015.06.003"},{"key":"9628_CR6409","doi-asserted-by":"crossref","unstructured":"Chiu C T, Chiang W F, Chuang C Y, Chang S W. Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw \u2013 a serial case analysis. J Oral Maxillofac Surg 2010; 68: 1055\u20131063.","DOI":"10.1016\/j.joms.2009.12.030"},{"key":"9628_CR6411","doi-asserted-by":"crossref","unstructured":"Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134: 620\u2013623.","DOI":"10.1111\/j.1365-2141.2006.06230.x"},{"key":"9628_CR6413","doi-asserted-by":"crossref","unstructured":"Otsuru M, Fujiki Y, Soutome S et al. Risk factors for dental findings of the development of medication-related osteonecrosis of the jaw: investigation of 3734 teeth in cancer patients receiving high dose antiresorptive agents. J Dent Sci 2024; 19: 203\u2013210.","DOI":"10.1016\/j.jds.2023.04.026"},{"key":"9628_CR6415","doi-asserted-by":"crossref","unstructured":"Kajizono M, Sada H, Sugiura Y et al. Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull 2015; 38: 1850\u20131855.","DOI":"10.1248\/bpb.b15-00385"},{"key":"9628_CR6419","doi-asserted-by":"crossref","unstructured":"Peer A, Khamaisi M. Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res 2015; 94: 252\u2013260.","DOI":"10.1177\/0022034514560768"},{"key":"9628_CR6422","doi-asserted-by":"crossref","unstructured":"Kemp A P T, Ferreira V H C, Mobile R Z et al. Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients. Braz J Otorhinolaryngol 2022; 88: 683\u2013690.","DOI":"10.1016\/j.bjorl.2020.09.010"},{"key":"9628_CR6424","doi-asserted-by":"crossref","unstructured":"Coropciuc R, Coopman R, Garip M et al. Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents \u2013 a retrospective study of 240 patients. Bone 2023; 170: 116722.","DOI":"10.1016\/j.bone.2023.116722"},{"key":"9628_CR6427","doi-asserted-by":"crossref","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27: 5356\u20135362.","DOI":"10.1200\/JCO.2009.21.9584"},{"key":"9628_CR6429","doi-asserted-by":"crossref","unstructured":"Soutome S, Hayashida S, Funahara M et al. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor?. PLos One 2018; 13(7): e0201343.","DOI":"10.1371\/journal.pone.0201343"},{"key":"9628_CR6431","doi-asserted-by":"crossref","unstructured":"Otto S, Tr\u00f6ltzsch M, Jambrovic V et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?. J Craniomaxillofac Surg 2015; 43: 847\u2013854.","DOI":"10.1016\/j.jcms.2015.03.039"},{"key":"9628_CR6434","doi-asserted-by":"crossref","unstructured":"Arya R, Miles E, Sproat C, Patel D, Patel V. An institutional protocol including socket alveoplasty and primary closure following dental extractions for patients with an elevated risk of developing medication-related osteonecrosis of the jaw. Br Dent J 2024; 237: 645\u2013651.","DOI":"10.1038\/s41415-024-7968-5"},{"key":"9628_CR6436","doi-asserted-by":"crossref","unstructured":"Niibe K, Ouchi T, Iwasaki R, Nakagawa T, Horie N. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J Prosthodont Res 2015; 59: 3\u20135.","DOI":"10.1016\/j.jpor.2014.08.001"},{"key":"9628_CR6438","doi-asserted-by":"crossref","unstructured":"Reich W, Bilkenroth U, Schubert J, Wickenhauser C, Eckert A W. Surgical treatment of bisphosphonate-associated osteonecrosis: prognostic score and long-term results. J Craniomaxillofac Surg 2015; 43: 1809\u20131822.","DOI":"10.1016\/j.jcms.2015.07.035"},{"key":"9628_CR6440","doi-asserted-by":"crossref","unstructured":"Lorenzo-Pouso A I, P\u00e9rez-Say\u00e1ns M, Chamorro-Petronacci C et al. Association between periodontitis and medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. J Oral Pathol Med 2020; 49: 190\u2013200.","DOI":"10.1111\/jop.12963"},{"key":"9628_CR6443","doi-asserted-by":"crossref","unstructured":"Ueda N, Aoki K, Shimotsuji H et al. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer. J Bone Miner Metab 2021; 39: 623\u2013630.","DOI":"10.1007\/s00774-020-01195-x"},{"key":"9628_CR6446","doi-asserted-by":"crossref","unstructured":"Yamazaki T, Yamori M, Ishizaki T et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012; 41: 1397\u20131403.","DOI":"10.1016\/j.ijom.2012.06.020"},{"key":"9628_CR6448","doi-asserted-by":"crossref","unstructured":"Di Fede O, Panzarella V, Mauceri R et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018; 2018: 2684924.","DOI":"10.1155\/2018\/2684924"},{"key":"9628_CR6451","doi-asserted-by":"crossref","unstructured":"Yarom N, Abdalla-Aslan R, Migliorati C et al. MASCC\/ISOO clinical practice statement: imaging and clinical laboratory tests in the diagnosis and management of medication-related osteonecrosis of the jaw. Support Care Cancer 2025; 33: 852.","DOI":"10.1007\/s00520-025-09809-8"},{"key":"9628_CR6453","doi-asserted-by":"crossref","unstructured":"Cartau T, Michon J, Verdon R, Baldolli A. Oral tetracyclines for bone and joint infections: what do we know?. J Bone Jt Infect 2025; 10: 143\u2013154.","DOI":"10.5194\/jbji-10-143-2025"},{"key":"9628_CR6455","doi-asserted-by":"crossref","unstructured":"Warner A J, Hathaway-Schrader J D, Lubker R, Davies C, Novince C M. Tetracyclines and bone: unclear actions with potentially lasting effects. Bone 2022; 159: 116377.","DOI":"10.1016\/j.bone.2022.116377"},{"key":"9628_CR6457","doi-asserted-by":"crossref","unstructured":"Thabit A K, Fatani D F, Bamakhrama M S, Barnawi O A, Basudan L O, Alhejaili S F. Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis 2019; 81: 128\u2013136.","DOI":"10.1016\/j.ijid.2019.02.005"},{"key":"9628_CR6459","doi-asserted-by":"crossref","unstructured":"Ewald F, Wuesthoff F, Koehnke R et al. Retrospective analysis of bacterial colonization of necrotic bone and antibiotic resistance in 98 patients with medication-related osteonecrosis of the jaw (MRONJ). Clin Oral Investig 2021; 25: 2801\u20132809.","DOI":"10.1007\/s00784-020-03595-9"},{"key":"9628_CR6462","doi-asserted-by":"crossref","unstructured":"Greenwald R A, Golub L M, Ramamurthy N S, Chowdhury M, Moak S A, Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone 1998; 22: 33\u201338.","DOI":"10.1016\/S8756-3282(97)00221-4"},{"key":"9628_CR6464","doi-asserted-by":"crossref","unstructured":"Golub L M, Lee H M, Ryan M E, Giannobile W V, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12\u201326.","DOI":"10.1177\/08959374980120010501"},{"key":"9628_CR6466","doi-asserted-by":"crossref","unstructured":"Bettany J T, Peet N M, Wolowacz R G, Skerry T M, Grabowski P S. Tetracyclines induce apoptosis in osteoclasts. Bone 2000; 27: 75\u201380.","DOI":"10.1016\/S8756-3282(00)00297-0"},{"key":"9628_CR6469","doi-asserted-by":"crossref","unstructured":"Tilakaratne A, Soory M. Anti-inflammatory actions of adjunctive tetracyclines and other agents in periodontitis and associated comorbidities. Open Dent J 2014; 8: 109\u2013124.","DOI":"10.2174\/1874210601408010109"},{"key":"9628_CR6472","doi-asserted-by":"crossref","unstructured":"Tabrizi R, Khiabani K, Shafiei S, Nosrati G, Moslemi H. Can topical phenytoin combined with tetracycline enhance the healing process in medication-related osteonecrosis of jaw? A comparative study. Natl J Maxillofac Surg 2022; 13: 195\u2013200.","DOI":"10.4103\/njms.njms_9_22"},{"key":"9628_CR6474","doi-asserted-by":"crossref","unstructured":"Aimetti M, Baima G, Aliyeva N et al. Influence of locally delivered doxycycline on the clinical and molecular inflammatory status of intrabony defects prior to periodontal regeneration: a double-blind randomized controlled trial. J Periodontal Res 2023; 58: 1096\u20131104.","DOI":"10.1111\/jre.13174"},{"key":"9628_CR6476","doi-asserted-by":"crossref","unstructured":"Abdellatife T. Efficacy of ozone gel, doxycycline saturated chitosan dressing versus alveogyl in pain alleviation and healing of alveolar osteitis in diabetic patients double blind randomized clinical trial. Egypt Dent J 2025; 71: 1213\u20131225.","DOI":"10.21608\/edj.2025.351790.3337"},{"key":"9628_CR6478","doi-asserted-by":"crossref","unstructured":"Gomes K D N, Alves A, Dutra P G P, Viana G S B. Doxycycline induces bone repair and changes in Wnt signalling. Int J Oral Sci 2017; 9: 158\u2013166.","DOI":"10.1038\/ijos.2017.28"},{"key":"9628_CR6481","doi-asserted-by":"crossref","unstructured":"Huang H, Zhao N, Li Q et al. The therapeutic effectiveness using fluorescence-guided surgery for MRONJ. Biomed Res Int 2022; 2022: 1650790.","DOI":"10.1155\/2022\/1650790"},{"key":"9628_CR6483","doi-asserted-by":"crossref","unstructured":"Russmueller G, Seemann R, Weiss K et al. The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep 2016; 6: 31604.","DOI":"10.1038\/srep31604"},{"key":"9628_CR6485","doi-asserted-by":"crossref","unstructured":"Ristow O, R\u00fcckschlo\u00df T, M\u00fcller M et al. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg 2019; 47: 491\u2013499.","DOI":"10.1016\/j.jcms.2018.12.014"},{"key":"9628_CR6488","doi-asserted-by":"crossref","unstructured":"Wilde F, Heufelder M, Winter K et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2011; 111: 153\u2013163.","DOI":"10.1016\/j.tripleo.2010.04.015"},{"key":"9628_CR6490","unstructured":"Freedman M, Stassen L F. Commonly used topical oral wound dressing materials in dental and surgical practice \u2013 a literature review. J Ir Dent Assoc 2013; 59: 190\u2013195."},{"key":"9628_CR6493","doi-asserted-by":"crossref","unstructured":"Ruggiero S L, Kohn N. Disease stage and mode of therapy are important determinants of treatment outcomes for medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2015; 73: 94\u2013100.","DOI":"10.1016\/j.joms.2015.09.024"},{"key":"9628_CR6495","doi-asserted-by":"crossref","unstructured":"Martins A S, Correia J A, Salvado F et al. Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws \u2013 a retrospective cohort study. J Craniomaxillofac Surg 2017; 45: 1736\u20131742.","DOI":"10.1016\/j.jcms.2017.07.014"},{"key":"9628_CR6498","doi-asserted-by":"crossref","unstructured":"Klingelh\u00f6ffer C, Zeman F, Meier J, Reichert T E, Ettl T. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws. J Craniomaxillofac Surg 2016; 44: 1694\u20131699.","DOI":"10.1016\/j.jcms.2016.08.001"},{"key":"9628_CR6501","doi-asserted-by":"crossref","unstructured":"AlDhalaan N A, BaQais A, Al-Omar A. Medication-related osteonecrosis of the jaw: a review. Cureus 2020; 12(2): e6944.","DOI":"10.7759\/cureus.6944"},{"key":"9628_CR6503","doi-asserted-by":"crossref","unstructured":"Corso A, Varettoni M, Zappasodi P et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007; 21: 1545\u20131548.","DOI":"10.1038\/sj.leu.2404682"},{"key":"9628_CR6505","doi-asserted-by":"crossref","unstructured":"Van Poznak C, Somerfield M R, Barlow W E et al. Role of Bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology cancer care ontario focused guideline update. J Clin Oncol 2017; 35: 3978\u20133986.","DOI":"10.1200\/JCO.2017.75.4614"},{"key":"9628_CR6508","doi-asserted-by":"crossref","unstructured":"AlRowis R, Aldawood A, AlOtaibi M et al. Medication-related osteonecrosis of the jaw (MRONJ): a review of pathophysiology, risk factors, preventive measures and treatment strategies. Saudi Dent J 2022; 34: 202\u2013210.","DOI":"10.1016\/j.sdentj.2022.01.003"},{"key":"9628_CR6510","doi-asserted-by":"crossref","unstructured":"O'Halloran M, Boyd N M, Smith A. Denosumab and osteonecrosis of the jaws \u2013 the pharmacology, pathogenesis and a report of two cases. Aust Dent J 2014; 59: 516\u2013519.","DOI":"10.1111\/adj.12217"},{"key":"9628_CR6512","doi-asserted-by":"crossref","unstructured":"Hoefert S, Yuan A, Munz A, Grimm M, Elayouti A, Reinert S. Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ). J Craniomaxillofac Surg 2017; 45: 570\u2013578.","DOI":"10.1016\/j.jcms.2017.01.013"},{"key":"9628_CR6515","doi-asserted-by":"crossref","unstructured":"Owosho A A, Blanchard A, Levi L et al. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: a series of thirteen patients. J Craniomaxillofac Surg 2016; 44: 265\u2013270.","DOI":"10.1016\/j.jcms.2015.12.005"},{"key":"9628_CR6518","doi-asserted-by":"crossref","unstructured":"Hinson A M, Siegel E R, Stack B C Jr. Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis. J Oral Maxillofac Surg 2015; 73: 53\u201362.","DOI":"10.1016\/j.joms.2014.07.012"},{"key":"9628_CR6520","doi-asserted-by":"crossref","unstructured":"Hayashida S, Yanamoto S, Fujita S et al. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. J Bone Miner Metab 2020; 38: 126\u2013134.","DOI":"10.1007\/s00774-019-01035-7"},{"key":"9628_CR6522","doi-asserted-by":"crossref","unstructured":"Kim Y H, Lee H K, Song S I, Lee J K. Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg 2014; 40: 206\u2013210.","DOI":"10.5125\/jkaoms.2014.40.5.206"}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41415-026-9628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-026-9628-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-026-9628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:24:44Z","timestamp":1783668284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41415-026-9628-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,10]]}},"alternative-id":["9628"],"URL":"https:\/\/doi.org\/10.1038\/s41415-026-9628-4","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"The authors declare that there are no conflicts of interest in connection with this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"Consent to publish","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"Written consent to publish was obtained from all patients for any patient-identifiable data\/images. All data and images were anonymised to protect patient confidentiality.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}]}}